Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Beta Bionics, Inc. Director's Dealing 2025

Jun 5, 2025

32351_dirs_2025-06-04_42cdefa3-8b15-4c7a-8abd-7b98883d6464.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2025-06-02

Reporting Person: Saint Sean (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-06-02 Common Stock S 943 $17.028 Disposed 107057 Direct
2025-06-02 Common Stock S 2185 $18.1489 Disposed 104872 Direct
2025-06-02 Common Stock S 311 $18.691 Disposed 104561 Direct

Footnotes

F1: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

F2: The weighted average sale price for the transaction reported was $17.028 and the range of prices were between $16.62 and $17.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3: The weighted average sale price for the transaction reported was $18.1489 and the range of prices were between $17.62 and $18.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F4: The weighted average sale price for the transaction reported was $18.691 and the range of prices were between $18.69 and $18.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.